Executive Vice President & General Manager of Diagnostic Services
Kyle Fetter has implemented and overseen the commercialization, billing, and reimbursement processes for over 70 unique molecular diagnostic companies releasing new high complexity laboratory testing services onto the health care market. He currently provides strategic direction as well as oversees the implementation process for molecular diagnostic companies at various stages of commercialization and third party payer contracting. He also oversees the development and commercialization of new web-based software products at XIFIN catered to high complexity testing laboratories. In addition to actively working with XIFIN’s large molecular diagnostic billing department, he consults with molecular diagnostic companies on projecting cash flow for non-covered services, implementing successful appeals strategies, and how to effectively manage the relationship between sales and reimbursement for new medical technology. Kyle regularly provides insights into the changing landscape of molecular diagnostic reimbursement via webinars, conferences, and XIFIN’s blog. He came to the healthcare industry with a background in technology funding and commercialization. Kyle has a B.A. from the University of Southern California and an M.B.A from the University of Utah.